Journals / Ankara Üniversitesi Veteriner Fakültesi Dergisi / 2019 / Cilt: 66 - Sayı: 4

Clinical significance of pretreatment Ca-P solubility product in 47 cats with chronic kidney disease

Kronik böbrek yetmezliği bulunan 47 kedide tedavi öncesi belirlenen Ca - P çarpımının klinik önemi

Pages
385–389
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, determination of pretreatment Ca-P solubility product in cats with different stages of CKD could be useful to modify and manage the life quality of cats with CKD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Chronic kidney disease (CKD) and mineral disorders are one of the most common reasons of cats.
📊
Key Findings & Data:The following groups were occurred based on serum creatinine (SCr) and urine specific gravity 5.0 mg/dl.
💡
Conclusion & Impact:In conclusion, determination of pretreatment Ca-P solubility product in cats with different stages of CKD could be useful to modify and manage the life quality of cats with CKD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Chronic kidney disease (CKD) and mineral disorders are one of the most common reasons of cats. Alterations in mineral metabolism occur in early stage of CKD and increasing the severity in advanced stages. In Turkey, although some clinical studies on CKD in cats are available, no data concerning the clinical significance of pretreatment Ca-P solubility product is present. The purpose of the current study was to determine of Ca-P solubility product and its association with the life quality of cats with CKD. Staging system for classifying cats with chronic kidney disease was based on IRIS guideline. The following groups were occurred based on serum creatinine (SCr) and urine specific gravity 5.0 mg/dl. Solubility product (calcium x phosphorus) was also defined. Although calcium levels were within reference ranges in groups, Ca-P product were above 72 mg2/dl2 in stage 3 and 4 cats. In conclusion, determination of pretreatment Ca-P solubility product in cats with different stages of CKD could be useful to modify and manage the life quality of cats with CKD.

Özet

Kronik böbrek yetmezliği (KBY) ve mineral metabolizması sorunları kedilerin yaygın klinik problemlerinden biridir. Mineral metabolizmasındaki değişimler KBY’nin erken aşamalarında başlamakta ve ileri aşamalarda ise şiddeti artmaktadır. Her ne kadar Ülkemizde KBY’li kedilerde yapılan bazı klinik çalışmalar mevcutsa da, bu çalışmaların hiç birinde tedavi öncesi belirlenen Ca-P çarpımının klinik önemine dair veri bulunmamaktadır. Çalışmanın amacı; KBY’li kedilerde Ca-P çarpımı ve yaşam kalitesiyle olan ilişkisini ortaya koymaktır. Çalışmada kronik böbrek yetmezliği olan kediler IRIS klasifikasyonuna göre sınıflandırıldı. Serum kreatinin (SCr) ve 1035’in altındaki idrar dansitesi baz alınarak böbrek yetmezliğinin şiddetine göre gruplar; 2. aşama= SCr 1.6 - 2.8 mg/dl; 3. aşama SCr = 2.9 - 5.0 mg/dl ve 4. aşama= SCr > 5.0 mg/dl olarak oluşturuldu. Kalsiyum fosfor çarpımı ayrıca tespit edildi. Her ne kadar gruplarda kalsiyum düzeyleri referans değerler arasındaysa da, kalsiyum fosfor çarpımı 3 ve 4. aşama kedilerde 72 mg2/dl2’nin üzerinde belirlendi. Sonuç olarak KBY’nin çeşitli aşamalarındaki kedilerde Ca-P çarpımının tedavi öncesi belirlenmesi KBY’li kedilerde yaşam kalitesinin yönetilmesinde faydalı olabilir.

🔖

Cite This Article

HAYDARDEDEOĞLU, A. E., ÇOLAKOĞLU, E. Ç., ALİHOSSEİNİ, H. (2022). Clinical significance of pretreatment Ca-P solubility product in 47 cats with chronic kidney disease. Ankara Üniversitesi Veteriner Fakültesi Dergisi, Cilt: 66 - Sayı: 4, 385–389. https://ajindex.com/articles/444511

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Albaaj F, Hutchinson AJ (2003): Hyperphosphatemia in renal failure, causes, consequences and current management. Drugs, 63, 577–96
  2. Altıntaş A, Üren N, Pekcan M, et al (2006): Kronik böbrek yetmezliği belirtileri gösteren kedilerde biyokimyasal ve hematolojik değişiklikler. Ankara Univ Vet Fak Derg, 53, 97-102
  3. Barber PJ, Elliott J (1995): Feline chronic renal failure: calcium homeostasis in 80 cases diagnosed between 1992 and 1995. J Small Anim Pract, 39, 108–11
  4. Bertazzolo W, Toscani L, Calcaterra S, et al (2003): Clinicopathological findings in five cats with paw calcification. JMFS, 5, 11-17
  5. Block GA, Hulbert-Shearon TE, Levin NW, et al (1998): Association of serum phosphorous and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis, 31, 607–17
  6. Bohmer E, Hanichen T, Lohss E (1991): Cutaneous calcinosis of the foodpads in a cat. Tierarztliche Praxis, 19, 88–95
  7. Boyd LM, Langston C, Thompson K, et al (2008): Survival in cats with naturally occurring chronic kidney disease (2000 –2002). J Vet Intern Med, 22, 1111–1117
  8. Börkü MK, Durgut R, Kurtdede A, et al (2000): Kronik böbrek yetmezligi belirtileri gösteren kedi ve köpeklerde klinik, laboratuvar ve patolojik bulgular. Ankara Univ Vet Fak Derg, 47, 288-289
  9. Broek DHN, Chang YM, Elliott J, et al (2017): Chronic kidney disease in cats and the risk of total hypercalcemia. J Vet Intern Med, 31, 465–475
  10. Chalhoub S, Langston C, Eatroff A (2011): Anemia of renal disease: what it is, what to do and what’s new. J Feline Med Surg, 13, 629–640
  11. Cooks M, Lothrorp CD (1994): Serum erythropoietin concentrations measured by radioimmunoassay in normal, polycythernic, and anemic dogs and cats. J Vet Intern Med, 8, 18-25
  12. Dibartola SP, Rutgers HC, Zack PM, et al (1987): Clinicopathologic findings associated with chronic renal disease in cats: 74 cases (1973–1984). J Am Vet Med Assoc, 190, 1196–1202
  13. Dibartola SP, Willard MD (2006): Disorders of phosphorous: hypophosphatemia and hyperphosphatemia. 195–209. In: SP Dibartola (Ed), Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice. Elsevier, Missouri
  14. Egenvall A, Nodtvedt A, Haggstrom J, et al (2009): Mortality of life-insured Swedish cats during 1999–2006: age, breed, sex, and diagnosis. J Vet Intern Med, 23, 1175–1183
  15. Elliot J, Rawlings JM, Markwell PJ, et al (2000): Survival of cats with naturally occurring chronic renal failure. Effect o